Skip to main content

Advertisement

SpringerLink
Log in

Future horizons for calcitonin: A U.S. perspective

  • Published:
Calcified Tissue International Aims and scope Submit manuscript

Summary

Injectable salmon calcitonin has been in use in the United States for more than a decade for the treatment of patients with postmenopausal osteoporosis, Paget's disease, and hypercalcemia, Sandoz Pharmaceuticals Corp. is currently in the process of developing a nasal formulation of salmon calcitonin. Studies are in progress to compare the efficacy of this nasal formulation with that of the injectable hormone in preventing bone loss and restoring bone, as well as in reducing pain associated with bone diseases. The rationale for development of a nasal formulation is to attempt to reduce the incidence of systemic side effects, inconvenience, and resulting noncompliance associated with the injectable product. In studies to date, the nasal form of calcitonin has been well tolerated by most subjects and was not notably associated with nasal irritation. The tolerability seen within the context of clinical trials suggests that a nasal formulation might be well accepted, even among asymptomatic osteoporotic patients. Asymptomatic patients with secondary osteoporosis due to steroid administration or solid organ transplantation may also be studied as possible candidates for the prophylactic use of this drug. Additional future research includes the development of an oral calcitonin agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Azria M (1989) The calcitonins: physiology and pharmacology. Karger, Basel, pp 1–152

    Google Scholar 

  2. Guttman S (1980) Chemistry and structure-activity-relationship of natural and synthetic calcitonins. In: Pecile A (ed) Calcitonin 1980 chemistry, physiology, pharmacology and clinical aspects. Excerpta Medica, Amsterdam, pp 11–24

    Google Scholar 

  3. Morikawa T, Munekata E, Sakakibara S (1976) Synthesis of eel calcitonin and Asu eel calcitonin: contribution of the disulphide bond to the hormonal activity. Experientia 32:1104–1106

    Article  PubMed  CAS  Google Scholar 

  4. Potts JR, Aurbach GD (1976) Chemistry of the calcitonins. In: Greep RO, Astwood EB (eds) Handbook of physiology. American Physiological Society 7/7, p 423

  5. Segre G, Bruni G, Dal Pra P (1985) Calcitonin pharmacokinetics. In: Pecile (ed) Calcitonin 1980: chemistry, physiology, pharmacology and clinical aspects. Excerpta Medica, Amsterdam, pp 99–107

    Google Scholar 

  6. Reginster JY, Gennari C, Mautalen C, et al (1990) Influence of specific anti-salmon calcitonin antibodies on biological effectiveness of nasal salmon calcitonin in Paget's disease of bone. Scand J Rheumatology 19:83–86

    CAS  Google Scholar 

  7. Gennari C, Gonnelli S, Chierichetti SM, et al (1985) Antibody problem in calcitonin administration. In: Pecile A (ed) Calcitonin. Elsevier Science Publishers BV, Amsterdam, pp 457–467

    Google Scholar 

  8. Gennari C, Agnusdei D (1989) Gain in bone mass and duration of antiresorptive treatment in established osteoporosis. Calcif Tissue Int 44 (suppl):S60

    Google Scholar 

  9. Heath H III, Sizemore GW (1977) Plasma calcitonin in normal man: differences between men and women. J Clin Invest 60:1135–1140

    Article  PubMed  CAS  Google Scholar 

  10. Milhaud G, Benezech-Lefevre M, Moukhtar MS (1980) Deficiency of calcitonin in age related osteoporosis. Biomedicine 29:272–276

    Google Scholar 

  11. Deftos LJ, Weisman H, Williams GW, et al (1980) Influence of age and sex on plasma calcitonin in human beings. N Engl J Med 302:1351–1353

    Article  PubMed  CAS  Google Scholar 

  12. Wallach S, Cohn SH, Atkins HL, et al (1977) Effect of salmon calcitonin on skeletal mass in osteoporosis. Curr Ther Res 22:556–572

    Google Scholar 

  13. Gruber HE, Ivey JL, Baylink DJ, et al (1984) Long-term calcitonin therapy in postmenopausal osteoporosis. Metabolism 33:295–303

    Article  PubMed  CAS  Google Scholar 

  14. Mazzuoli GF, Passeri M, Gennari C, et al (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38:3–8

    Article  PubMed  CAS  Google Scholar 

  15. Gennari C, Chierichetti SM, Bigazzi S, et al (1985) Comparative effects on bone mineral content of calcium and calcium plus salmon calcitonin given in two different regimens in postmenopausal osteoporosis. Curr Ther Res 38:455–464

    Google Scholar 

  16. Civitelli R, Gonnelli S, Zacchei F, et al (1988) Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. Clin Invest 82:1268–1274

    CAS  Google Scholar 

  17. Melanotte PL, Caira S (1986) Salmon calcitonin effect on proximal femur fracture repair in elderly patients. Curr Ther Res 39:449–454

    Google Scholar 

  18. Avioli LV (1990) Calcitonin therapy in osteoporotic syndromes. JAMWA 45:103–107

    PubMed  CAS  Google Scholar 

  19. Range JD, Welzel D (1987) Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Pharm 33:35–39

    Article  Google Scholar 

  20. Pasero GP, Gennari C, Di Munno O, et al (1985) Prevention of glucocorticoid-induced osteopenia by calcitonin. In: Pecile A (ed) Calcitonin 1984: chemistry, physiology, pharmacology and clinical aspects. Excerpta Medica, Amsterdam, pp 315–323

    Google Scholar 

  21. Gennari C (1983) Clinical aspects of calcitonin in pain. Triangle 22:157–163

    Google Scholar 

  22. Pecile A (1983) Calcitonin and pain relief. Triangle 22:147–155

    Google Scholar 

  23. Laurian L, Oberman Z, Graf E, et al (1986) Calcitonin induced increase in ACTH, β-endorphin and cortisol secretion. Horm Metabol Res 18:268–271

    Article  CAS  Google Scholar 

  24. Levernieux J, Julien D, Caulin F (1984) A double blind study on the effect of calcitonin on pain and acute resorption related to recent osteoporotic crush fractures. In: Doepfner W (ed) Calcitonin 1984: selected short communications, International Calcitonin Symposium, Milan, 2–4 October 1984, Excerpta Medica, Amsterdam, pp 119–125

    Google Scholar 

  25. Chan KC, Fang D (1988) MiacalcicR (synthetic salmon calcitonin) in osteoporotic bone pain. In: Chestnut III CH (ed) Osteoporosis: epidemiology, clinical presentation, diagnosis and treatment. Excerpta Medica Asia Ltd, Hong Kong, pp 89–93

    Google Scholar 

  26. Lam KS (1988) Clinical evaluation of short term Miacalcic (synthetic salmon calcitonin) in osteoporotic bone pain. In: Chestnut III CH (ed) Osteoporosis: epidemiology, clinical presentation, diagnosis and treatment. Excerpta Medica Asia Ltd, Hong Kong, pp 81–86

    Google Scholar 

  27. Vinceneux PM, Pouchot JA (1989) Analgesic effect of salmon calcitonin in crushed vertebral fractures: double blind versus placebo studying 58 patients. J Bone Miner Res 4:(Suppl 1) S399

    Google Scholar 

  28. Gennari C, Chierichetti SM, Piolini M, et al (1985) Analgesic activity of salmon and human calcitonin against cancer pain: a double-blind, placebo-controlled clinical study. Curr Ther Res 38:298–308

    Google Scholar 

  29. Ustdal M, Dogan P, Soyuer A, et al (1989) Treatment of migraine with salmon calcitonin: effects on plasma beta-endorphin, ACTH and cortisol levels. Biomed Pharmacother 43:687–691

    Article  PubMed  CAS  Google Scholar 

  30. Miseria S, Torresi U, Piga A, et al (1989) Analgesia with epidural calcitonin in cancer patients. Tumori 75:183–184

    PubMed  CAS  Google Scholar 

  31. Stevenson JC (1988) Current management of malignant hypercalcaemia. Drugs 36:229–238

    PubMed  CAS  Google Scholar 

  32. Zanussi C, Marini U, Ferrini PLR, et al (1985) Calcitonin in multiple myetoma: a double blind controlled clinical trial. In: Pecile A (ed) Calcitonin 1984: chemistry, physiology, pharmacology and clinical aspects. Excerpta Medica, Amsterdam, pp 379–388

    Google Scholar 

  33. Kimura S, Sato Y, Matsubara H, et al (1986) A retrospective evaluation of the medical treatment of malignancy-associated hypercalcaemia. Jap J Can Res 77:85–91

    CAS  Google Scholar 

  34. Evans RA (1983) Treatment of Paget's disease of bone. Med J of Australia 1:159–163

    CAS  Google Scholar 

  35. Toh SH, Claunch BC, Brown PH (1978) Effect of calcitonin treatment on the natural course of bone demineralization in Paget's disease. J Clin Endo Metab 56:405–409

    Article  Google Scholar 

  36. Nagant de Deuxchaisnes C, Rombouts-Lindermans C, Huaux JP, et al (1977) Roentgenologic evaluation of the efficacy of calcitonin in Paget's bone disease. In: MacIntyre I, Szelke M (eds) Molecular endocrinology. Elsevier North Holland Biomedical Press, Amsterdam, pp 213–233

    Google Scholar 

  37. Woodhouse NJ, Chalmers AH, Wells IP, et al (1977) Paget's disease. Radiological changes occurring in untreated patients and those on salmon calcitonin therapy during two years' observation. Br J Radiol 50:699–705

    PubMed  CAS  Google Scholar 

  38. Data on file, Sandoz Pharmaceuticals.

  39. Eisinger J (1987) Tolerance clinique de la calcitonine en function du mode d'administration. Revue du Rhumatisme 54:65–67

    CAS  Google Scholar 

  40. Reginster JY, Franchimont P (1985) Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection. Clin and Exp Rheum 3:155–157

    CAS  Google Scholar 

  41. Christiansen C, Riis BJ, Podenphant J, et al (1987) Intranasal calcitonin in the treatment of postmenopausal osteoporosis. In: Christiansen C, Johansen JS, Riis BJ (eds) Osteoporosis. Osteopress, Copenhagen, pp 853–856

    Google Scholar 

  42. Dambacher MA, Ruegsegger P, Goldmann AR, et al (1987) Treatment of postmenopausal osteoporosis with calcitonin nasal-spray evaluated with quantitative computed tomography. In: Christiansen C, Johansen JS, Riis BJ (eds) Osteoporosi 1987. Osteopress, Copenhagen, pp 1271–1272

    Google Scholar 

  43. Agnusdei D, Gonnelli S, Camporeale A, et al (1989) Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis. Minerva Endocrinologica 14:169–176

    PubMed  CAS  Google Scholar 

  44. Overgaard K, Riis BJ, Christiansen C, et al (1989) Nasal calcitonin for treatment of established osteoporosis. Clin Endo 30:435–442

    CAS  Google Scholar 

  45. Hesch RD, Busch U, Prokop M, et al (1989) Increase of vertebral density by combination therapy with pulsatile 1-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif Tissue Int 44:176–180

    Article  PubMed  CAS  Google Scholar 

  46. Reginster JY, Denis D, Albert A, et al (1987) One-year, controlled, randomized trial of prevention of early postmenopausal bone loss by intranasal calcitonin. Lancet 2:1481–1483

    Article  PubMed  CAS  Google Scholar 

  47. Overgaard K, Riis BJ, Christiansen C (1988) The role of intranasal calcitonin in the treatment and prophylaxis of postmenopausal osteoporosis. J Bone Min Res 3 (Suppl 1):S162

    Google Scholar 

  48. Pun KK, Chan LW (1989) Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Therapeutics 11:205–209

    CAS  Google Scholar 

  49. Reginster JY, Albert A, Franchimont P (1985) Salmon calcitonin nasal spray in Paget's disease of bone: preliminary results in five patients. Calcif Tissue Int 37:577–580

    Article  PubMed  CAS  Google Scholar 

  50. Nagant de Deuxchaisnes C, Devogelaer JP, Huaux JP, et al (1985) Effect of a nasal spray of salmon calcitonin in normal subjects and in patients with Paget's disease of bone. In: Pecile A (ed) Calcitonin 1984. Elsevier Science Publishers. Amsterdam, pp 329–343

    Google Scholar 

  51. Giustina A, Macca C, Romanelli G, et al (1989) Salmon calcitonin nasal spray in the treatment of Paget's disease 80:599–602

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Sandoz Research Institute, Building 801, 59 Route 10, 07936, East Hanover, NJ, USA

    John H. Carstens Jr. & Joel D. Feinblatt

Authors
  1. John H. Carstens Jr.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joel D. Feinblatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carstens, J.H., Feinblatt, J.D. Future horizons for calcitonin: A U.S. perspective. Calcif Tissue Int 49 (Suppl 2), S2–S6 (1991). https://doi.org/10.1007/BF02561368

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02561368

Key words

Search

Navigation